Louis Garguilo

ARTICLES BY LOUIS

  • 3/20/2023

    Until her daughter was diagnosed with Infantile Neuroaxonal Dystrophy (INAD) in 2016, Leena Panwala had been content with her life as a new mom, and selling real estate as a profession. Today, she’s co-founder and president of INADcure Foundation, and outsourcing a novel gene therapy. 

  • 3/13/2023

    Recent studies show women in the pharma industry represent 61% of the workforce, considerably higher than other industries. However, the percentage of female leaders is significantly lower. I spoke to an up-and-coming professional about this.

  • 3/8/2023

    Biopharma organizations are often counseled to consider the strategy of “mirroring” your outsourcing activities. But what if this were the other way around – your CDMO effectively mirrored your organization? It’s an idea come to life via a partnership development management organization (PDMO) in Aguadilla, Puerto Rico.

  • 3/1/2023

    You need lentiviral vectors. Apparently, so do a lot of others. Demand for lentiviral vectors is estimated to surge at a compound annual growth rate (CAGR) of 11.4 % until 2032. I’ve learned of a location where you can grab some capacity – and related CGT services.

  • 2/27/2023

    In August of 2021, relatively overlooked because of other news swirling around our industry, Moderna became the anchor client in a new cleanroom on demand housed in a bridge facility in Massachusetts. In retrospect, it may have legitimized a new era in outsourcing.

  • 2/20/2023

    Does your process to select a CDMO emerge from within and without? Ryan Crisman, cofounder and Chief Technical Officer, Umoja Biopharma, Inc., says it should. And he's learned that from a wise consultant that became his full-time employee. Here are their 6 tips to successful CDMO partnerships.

  • 2/13/2023

    If any of you have thoughts of building internal development and manufacturing facilities (to supplement or augment your outsourcing,) this is a discussion for you. It describes how on cell-therapy company made key decisions.

  • 2/8/2023

    Bridge facilities have been built for cell and gene therapy (CGT) sponsors – and CDMOs – to access here-and-now available, fully outfitted GxP capacity. But bring your own skilled workers. Here's how it works.

  • 2/3/2023

    Nowadays, “biotechs” emerge with unique business models, are hybrids of one kind or another, and operate as developers, platform/technology creators and service providers rolled up into one glorious organization. I found another one at Umoja Biopharma, Inc., a Seattle, Washington-based cell-therapy company. 

  • 1/30/2023

    There are a number of varying and converging forces baring down on sponsors looking for CROs/CDMOs who can provide a full slate of services around their clinical-trial material. Both CDMOs and sponsors need to add or subtract from their strategies to adjust.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.